Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Impact of Liver Volume Changes on Radiation Therapy for Abdominal Cancers

Official title: The Effect of Liver Volume Variation on Stereotactic Body Radiation Therapy (SBRT) Planning and Delivery for Upper Abdominal Malignancies

Run by University of Pittsburgh · NCT06355895 · Data updated 2026-11-12

This study is testing how changes in liver size, caused by things like diet, affect the effectiveness of radiation therapy for people with upper abdominal cancers.

More Upper Abdominal Malignancies trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment17 (estimated)
SponsorUniversity of Pittsburgh
Academic / other
Drugs / interventionsRadiation
Locations1 site (Pittsburgh, Pennsylvania)
StatusRecruiting
StartedMay 16, 2024
Main results expectedMarch 31, 2028
Study endsMarch 31, 2028
Registry record updatedJune 11, 2026
Trial IDNCT06355895 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include individuals with primary or metastatic upper abdominal cancers who are scheduled to receive SBRT.

Probably not a fit

Patients who have previously received radiation therapy to the liver or those with contraindications to iodinated contrast will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates how variations in liver volume, influenced by factors such as diet and time of day, affect the planning and delivery of stereotactic body radiation therapy (SBRT) for upper abdominal malignancies. It aims to enhance the precision of SBRT by examining the implications of these volume changes on radiation dose distribution and treatment setup. Utilizing advanced imaging techniques like four-dimensional computed tomography, the study seeks to improve patient outcomes by minimizing errors in radiation delivery. Participants will undergo a standardized high-carbohydrate meal to assess its effect on liver volume.

Why it matters

Potential benefit: If successful, this study could lead to more accurate radiation therapy planning, reducing the risk of radiation-induced liver disease and improving treatment outcomes for patients with upper abdominal cancers.

How similar studies have gone: While the effects of respiratory motion on SBRT are well-documented, the specific impact of liver volume changes on radiation delivery is less understood, making this approach relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

• Have primary upper abdominal (pancreatic, bile duct, liver) cancer or upper abdominal metastases (liver, adrenal, upper abdominal lymph nodes) planned to undergo SBRT.

Exclusion Criteria:

* Had prior Radiation Therapy to the liver
* Contraindication to receipt of iodinated IV contrast for CT (such as renal insufficiency or allergy that cannot be overcome by premedication)
* Pregnancy/lactation OR woman of childbearing potential who is unable or unwilling to use adequate contraception during Radiation Therapy.
* Inability to fast.

Where it's running

  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania, United States
    Recruiting

Study contacts

  • Principal investigator: Susannah Ellsworth, MD — UPMC Hillman Cancer Center
  • Study coordinator: Samantha Demko, BSN
  • Email: albesl@upmc.edu
  • Phone: 412-623-1400

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.